blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2437772

EP2437772 - IMMUNOREGULATORY PEPTIDES AND METHODS OF USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.10.2018
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  03.11.2017
FormerGrant of patent is intended
Status updated on  07.02.2017
FormerExamination is in progress
Status updated on  09.12.2016
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL, IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
13Therapeutics, Inc.
2611 SW 3rd Avenue, Suite 200
Portland, OR 97201 / US
[2017/07]
Former [2012/15]For all designated states
13therapeutics, Inc.
2611 SW 3rd Avenue, Suite 200
Portland, OR 97201 / US
Inventor(s)01 / MCCOY, Sharon, L.
544 NE Floral Place
Portland OR 97232 / US
02 / HEFENEIDER, Steven, H.
7220 SW Northvale Way
Portland OR 97225 / US
 [2012/15]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2017/49]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2012/15]Roques, Sarah Elizabeth
J.A. Kemp & Co. 14 South Square Gray's Inn
London WC1R 5JJ / GB
Application number, filing date10784168.604.06.2010
[2017/49]
WO2010US37443
Priority number, dateUS20090220738P26.06.2009         Original published format: US 220738 P
US20090184438P05.06.2009         Original published format: US 184438 P
US20090256364P30.10.2009         Original published format: US 256364 P
US20090220745P26.06.2009         Original published format: US 220745 P
US20090184455P05.06.2009         Original published format: US 184455 P
[2012/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010141845
Date:09.12.2010
Language:EN
[2010/49]
Type: A1 Application with search report 
No.:EP2437772
Date:11.04.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 09.12.2010 takes the place of the publication of the European patent application.
[2012/15]
Type: B1 Patent specification 
No.:EP2437772
Date:06.12.2017
Language:EN
[2017/49]
Search report(s)International search report - published on:US09.12.2010
(Supplementary) European search report - dispatched on:EP12.06.2013
ClassificationIPC:A61K38/16, A61K38/02, A61K38/10, C07K14/00, C07K7/08, A61P29/00, A61P17/06, A61P17/00, A61P19/02
[2012/15]
CPC:
C07K7/06 (EP,US); A61K39/285 (US); A61P1/10 (EP);
A61P1/12 (EP); A61P1/14 (EP); A61P11/02 (EP);
A61P17/00 (EP); A61P17/04 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P21/00 (EP); A61P25/00 (EP);
A61P25/04 (EP); A61P27/16 (EP); A61P29/00 (EP);
A61P37/02 (EP); A61P37/08 (EP); A61P43/00 (EP);
C07K14/005 (EP,US); C07K14/07 (US); C07K14/47 (EP,US);
C07K7/08 (EP,US); A61K38/00 (EP,US); C07K2319/10 (EP,US);
C12N2710/24122 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/15]
Extension statesBANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:IMMUNREGULIERENDE PEPTIDE UND VERWENDUNGSVERFAHREN DAFÜR[2012/15]
English:IMMUNOREGULATORY PEPTIDES AND METHODS OF USE[2012/15]
French:PEPTIDES IMMUNORÉGULATEURS ET PROCÉDÉS D'UTILISATION[2012/15]
Entry into regional phase15.12.2011National basic fee paid 
15.12.2011Search fee paid 
15.12.2011Designation fee(s) paid 
15.12.2011Examination fee paid 
Examination procedure15.12.2011Examination requested  [2012/15]
02.01.2014Amendment by applicant (claims and/or description)
17.02.2015Despatch of a communication from the examining division (Time limit: M02)
23.04.2015Reply to a communication from the examining division
09.08.2016Communication of intention to grant the patent
07.12.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
08.02.2017Communication of intention to grant the patent
26.05.2017Fee for grant paid
26.05.2017Fee for publishing/printing paid
26.05.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.02.2015
Opposition(s)07.09.2018No opposition filed within time limit [2018/46]
Fees paidRenewal fee
26.06.2012Renewal fee patent year 03
10.06.2013Renewal fee patent year 04
12.06.2014Renewal fee patent year 05
10.06.2015Renewal fee patent year 06
27.06.2016Renewal fee patent year 07
27.10.2017Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
30.06.201708   M06   Fee paid on   27.10.2017
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.06.2010
AL06.12.2017
AT06.12.2017
CY06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
MK06.12.2017
NL06.12.2017
PL06.12.2017
PT06.12.2017
RO06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
TR06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IS06.04.2018
IE04.06.2018
LU04.06.2018
MT04.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
[2020/33]
Former [2020/31]HU04.06.2010
AT06.12.2017
CY06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
MK06.12.2017
NL06.12.2017
PL06.12.2017
PT06.12.2017
RO06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
TR06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE04.06.2018
LU04.06.2018
MT04.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
Former [2020/27]HU04.06.2010
AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
PT06.12.2017
RO06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
TR06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE04.06.2018
LU04.06.2018
MT04.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
Former [2020/16]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
TR06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE04.06.2018
LU04.06.2018
MT04.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
Former [2020/08]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE04.06.2018
LU04.06.2018
MT04.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
Former [2019/24]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE04.06.2018
LU04.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
Former [2019/21]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE04.06.2018
LU04.06.2018
CH30.06.2018
LI30.06.2018
Former [2019/19]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE04.06.2018
LU04.06.2018
Former [2019/17]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
LU04.06.2018
Former [2019/15]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/52]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/51]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
SE06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/40]AT06.12.2017
CZ06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
SE06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/39]AT06.12.2017
CZ06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
IT06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
PL06.12.2017
SE06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/38]AT06.12.2017
CZ06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
PL06.12.2017
SE06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/37]CZ06.12.2017
EE06.12.2017
ES06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
PL06.12.2017
SE06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/34]ES06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
SE06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/24]ES06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
SE06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/23]ES06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
SE06.12.2017
NO06.03.2018
GR07.03.2018
Former [2018/22]ES06.12.2017
FI06.12.2017
LT06.12.2017
NO06.03.2018
Documents cited:Search[Y]US2006009391  (HEFENEIDER STEVEN H [US], et al) [Y] 1-15 * whole document esp. paragraphs [20,21,62,72, etc.] *;
 [YP]WO2010055500  (TRINITY COLLEGE DUBLIN [IE], et al) [YP] 1-15 * whole document esp. pages 35,45 *;
 [Y]  - MCCOY SHARON L ET AL, "Identification of a peptide derived from vaccinia virus A52R protein that inhibits cytokine secretion in response to TLR-dependent signaling and reduces in vivo bacterial-induced inflammation", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20050301), vol. 174, no. 5, ISSN 0022-1767, pages 3006 - 3014, XP002532542 [Y] 1-15 * whole document esp. abstract *
ExaminationUS2008039395
by applicantUS7192930
 US2008039395
    - TAKEDA, K.; S. AKIRA., "TLR signaling pathways", SEMINARS IN IMMUNOLOGY, (2004), vol. 16, doi:doi:10.1016/j.smim.2003.10.003, page 3, XP002331805

DOI:   http://dx.doi.org/10.1016/j.smim.2003.10.003
    - SCHNARE M.; G. M. BARTON; A. C. HOLT; K. TAKEDA; S. AKIRA; R. MEDZHITOV, "Toll-like receptor control activation of adaptive immune responses", NAT. IMMUNO, (2001), vol. 2, doi:doi:10.1038/ni712, page 947, XP001119054

DOI:   http://dx.doi.org/10.1038/ni712
    - GRANUCCI, F.; C. VIZZARDELLI; N. PAVELKA; S. FEAU; M. PERSICO; E. VIRZI; M. RESCIGNO; G. MORO; P. RICCIARDI-CASTAGNOLI, "Inducible II-2 production by dendritic cells revealed by global gene expression analysis", NAT. IMMUNOL, (2001), vol. 2, doi:doi:10.1038/ni0901-882, page 882, XP009006128

DOI:   http://dx.doi.org/10.1038/ni0901-882
    - KRIEG, A. M., "CpG motifs in bacterial DNA and their immune effects", ANN. REV. IMMUNOL., (2002), vol. 20, doi:doi:10.1146/annurev.immunol.20.100301.064842, page 709, XP009016455

DOI:   http://dx.doi.org/10.1146/annurev.immunol.20.100301.064842
    - TRINCHIERI, G., "Interleukin-12: a cytokine at the interface of inflammation and immunity", ADV. IMMUNOL., (1998), vol. 70, page 83
    - OZATO, K.; H. TSUJIMURA; T TAMURA, "Toll-like receptor signaling and regulation of cytokine gene expression in the immune system", BIOTECHNIQUES, (200210), page 66, XP001539678
    - YI, A. K.; J. G. YOON; S. J. YEO; S. C. HONG; B. K. ENGLISH; A. M. KRIEG, "Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Thl response", J. IMMUNOL., (2002), vol. 168, page 4711
    - FAN, J.; A. B. MALIK, "Toll-like receptor-4(TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors", NAT. MED., (2003), vol. 9, doi:doi:10.1038/nm832, page 315, XP008137565

DOI:   http://dx.doi.org/10.1038/nm832
    - MCCOY, S. L.; S. E. KURTZ; F. A. HAUSMAN; S. R. TRUNE; R. M. BENNETT; S. H. HEFENEIDER, "Activation of RAW264.7 macrophages by bacterial DNA and lipopolysaccharide increases cell surface DNA binding and internalization", J. BIOL. CHEM., (2004), vol. 279, page 17217
    - HOSHINO, K.; O. TAKEUCHI; T. KAWAI; H. SANJO; T. OGAWA; Y. TAKEDA; K. TAKEDA; S. AKIRA, "Cutting Edge: Toll-like receptor 4 (TLR4)-deficient mice are hyproresponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product", J. IMMUNOL., (1999), vol. 162, page 3749
    - HEMMI, H.; O. TAKEUCHI; T. KAWAI; T. KAISHO; S. SATO; H. SANJO; M. MATSUMO; K. HOSHINO; H. WAGNER; K. TAKEDA, "A Toll-like receptor recognizes bacterial DNA", NATURE, (2000), vol. 408, doi:doi:10.1038/35047123, page 740, XP002221246

DOI:   http://dx.doi.org/10.1038/35047123
    - HAYASHI, F.; K. D. SMITH; A. OZINSKY; T. R. HAWN; E. C. YI; D. R. GOODLETT; J. K. ENG; S. AKIRA; D, M. UNDERHILL; A. ADEREM, "The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5", NATURE, (2001), vol. 410, doi:doi:10.1038/35074106, page 1099, XP002210843

DOI:   http://dx.doi.org/10.1038/35074106
    - TAKEDA, K.; T. KAISHO; S. AKIRA, "Toll-like receptors", ANN. REV. IMMUNOL., (2003), vol. 21, doi:doi:10.1146/annurev.immunol.21.120601.141126, page 335, XP002470283

DOI:   http://dx.doi.org/10.1146/annurev.immunol.21.120601.141126
    - AKIRA, S, "Mammalian Toll-like receptors", CURR. OPIN. IMMUNOL., (2003), vol. 15, doi:doi:10.1016/S0952-7915(02)00013-4, page 5, XP004399365

DOI:   http://dx.doi.org/10.1016/S0952-7915(02)00013-4
    - BOWIE, A.; E. KISS-TOTH; J. A. SYMONS; G. L. SMITH; S. K. DOWER; L. A. J. O'NEILL, "A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling", PROC. NATL. ACAD. SCI. U.S.A., (2000), vol. 97, doi:doi:10.1073/pnas.160027697, page 10162, XP002264055

DOI:   http://dx.doi.org/10.1073/pnas.160027697
    - O'NEILL L, "The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence", BIOCHEM. SOC. TRANS., (2000), vol. 28, page 557, XP002264057
    - BELLOWS, C. F.; R. F. GARRY; B. M. JAFFE, "Vaccinia virus-induced inhibition of nitric oxide production", J. SURG. RES, (2003), vol. ILL, page 127
    - HARTE, M. T.; I. R. HAGA; G. MALONEY; P. GRAY; P. C. READING; N. W. BARTLETT; G. L. SMITH; A. BOWIE; L. A. J. O'NEILL, "The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense", J. EXP. MED., (2003), vol. 197, doi:doi:10.1084/jem.20021652, page 343, XP002264056

DOI:   http://dx.doi.org/10.1084/jem.20021652
    - YI, A. K.; A. M. KRIEG, "Cutting Edge: Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA", J. IMMUNOL., (1998), vol. 161, page 4493
    - WENDER, P. A.; D. J. MITCHELL; K. PATTABIRAMAN; E. T. PELKEY; L. STEINMAN, "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters", PROC. NATL. ACAD. SCI. U.S.A., (2000), vol. 97, doi:doi:10.1073/pnas.97.24.13003, page 13003, XP002347555

DOI:   http://dx.doi.org/10.1073/pnas.97.24.13003
    - BARZILAI A.; B. DEKEL; R. DAGAN; E. LEIBOVITZ, "Middle ear effusion II-6 concentration in bacterial and non-bacterial acute otitis media", ACTA PAEDIATR, (2000), vol. 89, page 1068
    - TAKEDA, K.; S. AKIRA, "TLR signaling pathways", SEMIN. IMMUNOL, (2004), vol. 16, doi:doi:10.1016/j.smim.2003.10.003, page 3, XP002331805

DOI:   http://dx.doi.org/10.1016/j.smim.2003.10.003
    - JANSSENS, S.; R. BEYAERT, "Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members", MOL. CELL, (2003), vol. 11, doi:doi:10.1016/S1097-2765(03)00053-4, page 293, XP008110900

DOI:   http://dx.doi.org/10.1016/S1097-2765(03)00053-4
    - DAUN, J. M.; M. J. FENTON, "Interleukin-1/Toll receptor family members: receptor structure and signal transduction pathways", J. INTERFERON CYTOKINE RES., (2000), vol. 20, page 843
    - BARTON, G. M.; R. MEDZHITOV, "Linking Toll-like receptors to IFN-a/p expression", NAT. IMMUNOL., (2003), vol. 4, page 432
    - KARASEN R. M.; Y. SUTBEYAZ; B. AKTAN; H. OZDEMIR; C. GUNDOGU, "Effect of web 2170 BS, platelet activating factor receptor inhibitor, in the guinea pig model of middle ear inflammation", ANN OTOL RHINOL LARYNGOL, (2000), vol. 109, page 549
    - DALY, K. A.; L. L. HUNTER; G. S. GIEBINK, "Chronic Otitis Media with Effusion", PEDIATRICS IN REVIEW, (1999), vol. 20, page 85
    - KUBBA H.; J. P. PEARSON; J. P. BIRCHALL, "The aetiology of otitis media with effusion: a review", CLIN OTOLARYNGOL, (2000), vol. 25, page 181
    - O'NEILL, L. A. J., "Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases", CURR. OPIN. PHARM., (2003), vol. 3, page 396
    - ZUANY-AMORIM, C.; J. HASTEWELL; C. WALKER, "Toll-like receptors as potential therapeutic targets for multiple diseases", NAT. REV. DRUG DISCOV, (2002), vol. 1, doi:doi:10.1038/nrd914, page 797, XP002480890

DOI:   http://dx.doi.org/10.1038/nrd914
    - IKEZOE, T.; Y. YANG; D. HEBER; H. TAGUCHI; H. P. KOEFFLER, "PC-SPES: A potent inhibitor of nuclear factor- B rescues mice from lipopolysaccharide-induced septic shock", MOL. PHARMACOL., (2003), vol. 64, page 1521
    - DELGADO, M.; C. ABAD; C. MARTINEZ; M. G. JUARRANZ; J. LECETA; D. GANEA; R. P. GOMARIZ, "PACAP in immunity and inflammation", ANN. N.Y. ACAD. SCI., (2003), vol. 992, page 141
    - BASU, S.; M. J. FENTON, "Toll-like receptors: function and roles in lung disease", AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOL., (2004), vol. 286, page L887
    - KOPP, E.; S. GHOSH, "Inhibition of NF-kappa B by sodium salicylate and aspirin", SCIENCE, (1994), vol. 265, page 956
    - ALMAWI, W. Y.; O. K. MELEMEDJIAN, "Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids", J. MOL. ENDOCRINOL., (2002), vol. 28, doi:doi:10.1677/jme.0.0280069, page 69, XP002542461

DOI:   http://dx.doi.org/10.1677/jme.0.0280069
    - ANDREAKOS, E. T.; B. M. FOXWELL; F. M. BRENNAN; R. N. MAINI; M. FELDMANN, "Cytokines and anti-cytokine biologicals in autoimmunity: present and future", CYTOKINE GROWTH FACTOR REV., (2002), vol. 13, page 299
    - MENG, G.; M. RUTZ; M. SCHIEMANN; J. METZGER; A. GRABIEC; R. SCHWANDNER; P. B. LUPPA; F. EBEL; D. H. BUSCH; S. BAUER, "Antagonistic antibody prevents Toll-like receptor 2-driven lethal shock-like syndromes", J. CLIN. INVEST., (2004), vol. 113, doi:doi:10.1172/JCI200420762, page 1473, XP002668418

DOI:   http://dx.doi.org/10.1172/JCI200420762
    - SWEET, M. J.; B. P. LEUNG; D. KANG; M. SOGAARD; K. SCHULZ; V. TRAJKOVIC; C. C. CAMPBELL; D. XU; F. Y. LIEW, "A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression", J. IMMUNOL., (2001), vol. 166, doi:doi:10.4049/jimmunol.166.11.6633, page 6633, XP009160422

DOI:   http://dx.doi.org/10.4049/jimmunol.166.11.6633
    - BRINT, E. K.; D. XU; H. LIU; A. DUNNE; A. N. MCKENZIE; L. A. O'NEILL; F. Y. LIEW, "ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance", NAT. IMMUNOL, (2004), vol. 5, doi:doi:10.1038/ni1050, page 373, XP002995949

DOI:   http://dx.doi.org/10.1038/ni1050
    - CHUANG, T. H.; R. J. ULEVITCH, "Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors", NAT. IMMUNOL., (2004), vol. 5, page 495
    - BARTFAI, T.; M. M. BEHRENS; S. GAIDAROVA; J. PEMBERTON; A. SHIVANYUK; J. REBEK, JR., "A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses", PROC. NATL. ACAD. SCI. U.S.A., (2003), vol. 100, doi:doi:10.1073/pnas.0932746100, page 7971, XP002341589

DOI:   http://dx.doi.org/10.1073/pnas.0932746100
    - MCCOY, S. L.; KURTZ, S. E.; MACARTHUR, C. J.; TRUNE, D. R; HEFENEIDER, S. H., "Identification of a Peptide Derived from Vaccinia Virus A52R Protein That Inhibits Cytokine Secretion in Response to TLR-Dependent Signaling and Reduces In Vivo Bacterial-induced Inflammation", JOURNAL OF IMMUNOLOGY, (2005), vol. 174, pages 3006 - 3014, XP002532542
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.